MediWound Reports Positive Results in Leg Ulcer Trial

Israeli biotherapeutic solutions for tissue repair developer MediWound Ltd. reported positive results on a Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers (VLUs). The study met its primary endpoint, demonstrating that patients treated with EscharEx had a statistically significant higher incidence of complete debridement compared to the gel, with a p-value of 0.004.

For the full article

Mr. Ofer Gonen, Cohort #2, Mr. Sharon Malka, Cohort #4 & Mr. Assaf Segal, Cohort #3